📣THURSDAY: Join us for our upcoming event! We will gather experts to discuss recent developments and future applications of real-world evidence and real-world data policy. The draft agenda has been updated and now includes a speaker lineup. We look forward to hearing insights from these speakers: Stella Chang, OMNY Health Laura DiAngelo, AgencyIQ Hussein Ezzeldin, U.S. Food and Drug Administration Lee Fleisher, Rubrum Advising Richard Forshee, U.S. Food and Drug Administration Joe Franklin, Verily Life Sciences Inmaculada Hernandez, University of California San Diego Nicholaas Honig, Aetion, Inc. Dena Jaffe, Oracle Health Annette James, American Academy of Actuaries Rodrigo Refoios Camejo, GSK David Rhew, Microsoft Katy Sadowski, Boehringer Ingelheim Jaime Smith, Parexel Joanne Walker, The Evidence Base Learn more and register here: https://duke.is/w/ahyn
Duke-Margolis Institute for Health Policy’s Post
More Relevant Posts
-
The Food and Drug Administration has indicated diversity and representation requirements will be a focus of future regulations around clinical trials – and a key means of bridging gaps in representation for underserved populations. However, knowing what evidence is required to develop digital health technologies (DHTs) in the absence of established standards remains a moving target. On Tuesday, April 30 at 2 PM ET join Nathalie Horowicz-Mehler, PhD and Marta Villarraga of Exponent, and Blake Wilson, J.D., M.S. of Hogan Lovells as they present five questions for life sciences firms to consider when evaluating the use of DHTs in clinical trials. These proposed questions can have an impact on the level of evidence generated to support the development of new treatments, as well as diversity and representation requirements. Register now at https://lnkd.in/eXtVdYi6
-
-
💊🚀Do you often forget to take your meds? Did you know this phenomenon has a name, multiple consequences, and a project designed to address them? A new RIVA Illustrations production to spread awareness about ADHERENCE thanks to the collaboration with Gaye Hafez 💊🚀 #digitalhealth #pharmacy #primarycare #pharmacology #MATech COST Association - European Cooperation in Science and Technology
🚀 Exciting News from the World Adherence Forum! 🚀 On August 30, we had an incredible meeting with over 70 participants spanning industry, clinical organizations, policymakers, academia, and patient representatives. The discussion focused on a crucial topic: #medicationadherence and digital solutions. To amplify the importance of this issue in public health, we are thrilled to unveil a new comic designed to raise awareness and spark conversations. A huge thank you to RIVA Illustrations, Fiammetta Ghedini and Luigi Critone for their exceptional creativity and collaboration in bringing this concept to life! ✨Check out the comic and join us in spreading the message that adherence matters. Together, we can make a significant impact on public health! #digitalhealth #pharmacy #primarycare #pharmacology #MATech COST Association - European Cooperation in Science and Technology Created by WG4: Gaye Hafez, Björn Wettermark, Francisca Leiva-Fernández, Ana Tomas Petrovic, Cristina Ghiciuc, Hanna Gottlieb, Elisabetta Poluzzi, Job van Boven
-
Join us for this excellent session on a topic of critical importance to companies in the drug and device industries.
The Food and Drug Administration has indicated diversity and representation requirements will be a focus of future regulations around clinical trials – and a key means of bridging gaps in representation for underserved populations. However, knowing what evidence is required to develop digital health technologies (DHTs) in the absence of established standards remains a moving target. On Tuesday, April 30 at 2 PM ET join Nathalie Horowicz-Mehler, PhD and Marta Villarraga of Exponent, and Blake Wilson, J.D., M.S. of Hogan Lovells as they present five questions for life sciences firms to consider when evaluating the use of DHTs in clinical trials. These proposed questions can have an impact on the level of evidence generated to support the development of new treatments, as well as diversity and representation requirements. Register now at https://lnkd.in/eXtVdYi6
-
-
The Food and Drug Administration has indicated that achieving health equity is a priority. Please join me and my colleague Marta Villarraga of Exponent, and Blake Wilson, J.D., M.S. of Hogan Lovells today, April 30 at 2 PM ET as we present five questions for life sciences firms to consider when evaluating the role of digital health technologies (DHTs) in meeting health equity goals in clinical trials. #healthequity #DigitalHealth #MedicalDevices #Exponent
The Food and Drug Administration has indicated diversity and representation requirements will be a focus of future regulations around clinical trials – and a key means of bridging gaps in representation for underserved populations. However, knowing what evidence is required to develop digital health technologies (DHTs) in the absence of established standards remains a moving target. Please join Nathalie Horowicz-Mehler, PhD and Marta Villarraga of Exponent, and Blake Wilson, J.D., M.S. of Hogan Lovells TOMORROW, April 30 at 2 PM ET as they present five questions for life sciences firms to consider when evaluating the use of DHTs in clinical trials. These proposed questions can have an impact on the level of evidence generated to support the development of new treatments, as well as diversity and representation requirements. Register now at https://lnkd.in/eXtVdYi6
-
-
Postodoc Researcher and Adjunct lecturer at University of Thessaly - ENABLE contact - Bioinformatics Scientist at StoreGene
Smart solutions for better health by ENABLE Adherence. This great comic creatively illustrates our mission. 🇪🇺 💡
🚀 Exciting News from the World Adherence Forum! 🚀 On August 30, we had an incredible meeting with over 70 participants spanning industry, clinical organizations, policymakers, academia, and patient representatives. The discussion focused on a crucial topic: #medicationadherence and digital solutions. To amplify the importance of this issue in public health, we are thrilled to unveil a new comic designed to raise awareness and spark conversations. A huge thank you to RIVA Illustrations, Fiammetta Ghedini and Luigi Critone for their exceptional creativity and collaboration in bringing this concept to life! ✨Check out the comic and join us in spreading the message that adherence matters. Together, we can make a significant impact on public health! #digitalhealth #pharmacy #primarycare #pharmacology #MATech COST Association - European Cooperation in Science and Technology Created by WG4: Gaye Hafez, Björn Wettermark, Francisca Leiva-Fernández, Ana Tomas Petrovic, Cristina Ghiciuc, Hanna Gottlieb, Elisabetta Poluzzi, Job van Boven
-
The Food and Drug Administration has indicated diversity and representation requirements will be a focus of future regulations around clinical trials – and a key means of bridging gaps in representation for underserved populations. However, knowing what evidence is required to develop digital health technologies (DHTs) in the absence of established standards remains a moving target. Please join Nathalie Horowicz-Mehler, PhD and Marta Villarraga of Exponent, and Blake Wilson, J.D., M.S. of Hogan Lovells TOMORROW, April 30 at 2 PM ET as they present five questions for life sciences firms to consider when evaluating the use of DHTs in clinical trials. These proposed questions can have an impact on the level of evidence generated to support the development of new treatments, as well as diversity and representation requirements. Register now at https://lnkd.in/eXtVdYi6
-
-
Articulating Added Value in Clinical Trials 🔬 At our clinics, we bring unmatched value to our clients and partners by maintaining complete control over our data and protocols. By owning and operating our clinics, we manage everything in-house—from protocol development by our science team to the execution of the trials. This minimizes external noise and variability, ensuring consistent and reliable data. Why does this matter? For functional foods, where effect sizes are often small, this consistency is crucial. By eliminating external variations, we ensure that the data remains consistent and reliable, ultimately providing our clients with more precise and beneficial trial outcomes. Trust in our process, rely on our results. #ClinicalTrials #FunctionalFoods #DataIntegrity #Research #Science #HealthcareInnovation #Atlantia
-
-
I could not be more proud of the rigor and thinking that my team - Regulatory Science and Study Innovation brings to our work in #naturalhistorystudies and to real world evidence generation in general. Come join us for a webinar on Monday July 15! #IQVIA #RWE #RegulatoryScience
Through early and strategic planning, natural history studies have the power to generate valuable real world evidence (#RWE) across the total product lifecycle. Strategically designed and timed #naturalhistorystudies can lead to more efficient and effective use of this data to address key evidence gaps. Learn how these methods have helped sponsors mitigate risks and enhance interactions with health authorities, driving success in regulatory submissions: https://bit.ly/3zBZSkV Julien Heidt, Tiffany A. Mercado, Chinenye Ugoji, #Webinar #RegulatoryAffairs #EvidenceBasedDecisionMaking
-
-
Join us for our upcoming webinar! Our expert panel will dive deep into essential strategies to enhance your evidence-based decision-making processes and achieve regulatory success. Don't miss this opportunity to gain valuable insights and practical knowledge. Help us spread the word! Like, share, and comment to let your network know about this must-attend event. #Webinar #NaturalHistoryStudies #EvidenceBasedDecisionMaking #RegulatorySuccess #Pharma #MedTech #HealthcareInnovation
Through early and strategic planning, natural history studies have the power to generate valuable real world evidence (#RWE) across the total product lifecycle. Strategically designed and timed #naturalhistorystudies can lead to more efficient and effective use of this data to address key evidence gaps. Learn how these methods have helped sponsors mitigate risks and enhance interactions with health authorities, driving success in regulatory submissions: https://bit.ly/3zBZSkV Julien Heidt, Tiffany A. Mercado, Chinenye Ugoji, #Webinar #RegulatoryAffairs #EvidenceBasedDecisionMaking
-
-
July 15 webinar: Strategically designed and timed #naturalhistorystudies can lead to more efficient and effective use of this data to address key evidence gaps.
Through early and strategic planning, natural history studies have the power to generate valuable real world evidence (#RWE) across the total product lifecycle. Strategically designed and timed #naturalhistorystudies can lead to more efficient and effective use of this data to address key evidence gaps. Learn how these methods have helped sponsors mitigate risks and enhance interactions with health authorities, driving success in regulatory submissions: https://bit.ly/3zBZSkV Julien Heidt, Tiffany A. Mercado, Chinenye Ugoji, #Webinar #RegulatoryAffairs #EvidenceBasedDecisionMaking
-
